Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,442 across all filing types
Latest filing 2021-04-11 Investor Presentation
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Imugene HER-Vaxx Presentation at AACR 2021 Meeting 3 pages 131.9KB
Investor Presentation Classification · 95% confidence The document is an ASX announcement from Imugene Limited about a presentation given at the American Association for Cancer Research 2021 Annual Meeting. It details interim clinical trial results and scientific data related to their HER-2 cancer immunotherapy program. The content focuses on clinical trial data, survival analysis, and immunotherapy efficacy, presented at a scientific conference. There is no indication that this is a full financial report, audit report, earnings release, or regulatory filing. It is a presentation announcement related to clinical and scientific progress, aimed at investors and the public. The document length is 7,386 characters, which is substantive but the content is clearly a presentation summary rather than a formal financial or regulatory report. Therefore, the best fitting category is Investor Presentation (IP).
2021-04-11 English
Imugene Oncolytic Virus Presentation at AACR 2021 Meeting 2 pages 106.2KB
Regulatory Filings Classification · 90% confidence The document is an ASX announcement from Imugene Limited dated April 12, 2021, describing pre-clinical data presented at the American Association for Cancer Research 2021 Annual Meeting. It discusses scientific and clinical research results related to their oncolytic virus program. The document is relatively short (4232 characters) and serves as a news release or announcement about the presentation of research data rather than a detailed financial or regulatory report. There is no indication of financial statements, management discussion, voting results, or regulatory filings. It is not a report publication announcement since it contains substantive information about the pre-clinical data and the presentation itself. The content fits best under a general regulatory announcement or company news update category. Given the available categories, the closest fit is Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other specific categories.
2021-04-11 English
Final Highest Dose in Phase 1 Clinical Trial of PD-VAXX 3 pages 130.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene Limited about the dose escalation to the final highest dose in a Phase I clinical trial of their immunotherapy PD1-Vaxx. It discusses clinical trial progress, safety data, early efficacy signals, and regulatory approval for trial sites. There are no financial statements, detailed financial analysis, or comprehensive management discussion of financial results. The document is a corporate announcement about clinical trial progress and regulatory updates rather than a financial report or detailed investor presentation. It is not a report publication announcement since it contains substantive information rather than just a notice of report availability. The content fits best under a general regulatory announcement category related to clinical trial progress and company updates. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-04-06 English
Proposed issue of Securities - IMU 6 pages 29.9KB
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding a proposed issue of securities by Imugene Limited. It details the number of securities to be issued, the issue price, the class of securities, and other related information such as approvals and fees. There is no financial performance data, management discussion, or audit information. The document is focused on informing about a capital raising activity, specifically a placement or other type of securities issue. This fits the definition of a Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about the securities issue, not just a brief notice or link to a report, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2021-03-31 English
Appendix 2A 15 pages 432.6KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 2A Application for quotation of +securities' and is structured as a form for applying for quotation of securities on the ASX (Australian Securities Exchange). It includes detailed questions about the entity, the type of securities being quoted, dates of previous announcements (Appendix 3B), and other regulatory compliance information related to securities issuance and quotation. This type of document is a regulatory announcement related to capital markets activity, specifically the application for quotation of new securities. It is not a financial report, earnings release, management discussion, or any other type of report. It is also not a report publication announcement but a formal regulatory filing to the exchange. According to the filing definitions, this fits best under 'Capital/Financing Update (CAP)' as it relates to updates on company fundraising, financing activities, or capital structure changes through the issuance and quotation of securities.
2021-03-31 English
Appendix 3G 13 pages 367.8KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3G form submitted to the ASX, which is a notification of the issue, conversion, or payment up of equity securities. It details the issuance of unlisted options under an employee incentive scheme, including the number of securities, their terms, and related information. This type of filing is a formal announcement regarding changes in the company's capital structure, specifically the issuance of new securities. It is not a full financial report, earnings release, or management discussion, but rather a regulatory announcement about capital changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and content confirm it is a substantive announcement, not just a brief notice or a report publication announcement.
2021-03-11 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.